DV
Dividend Vision

CGEM — Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. (CGEM)

Total return is -32.0% over the past 5.6 years, 151.3 points behind SPY at 119.3%. Its deepest 1-year drawdown was 29.8%.

Cullinan Therapeutics, Inc. is an equity stock that operates in the biotechnology sector, focused on therapeutic development rather than dividend distribution. The stock does not pay distributions and carries no listed expense ratio, as it is an individual security rather than a traditional ETF structure. This asset appeals primarily to growth-oriented investors seeking exposure to the biotechnology industry, rather than those pursuing current income strategies.

CGEM key facts

Asset type
Stock
Asset class
Equity
Inception date
01/08/2021
Distribution frequency
None
Last close
$20.34
Market cap
$1,250,056,704
Average volume
565800.0
Beta
-0.023
Payout ratio
0.0
Forward P/E
6.7385
EPS
$-3.11